Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3475 and Peginterferon Alfa-2b in Advanced Melanoma
NCT02112032Phase 1Completed
- Start
- Jul 2014
- Primary completion
- Apr 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in melanoma (3 arms). Primary endpoint: Number of Participants with Serious and Non-Serious Adverse Events at 29 days. Started Jul 2014; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02112032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02112032.